Cargando…
Immunotherapy in non-small cell lung cancer: rationale, recent advances and future perspectives
Lung cancer, with non-small cell lung cancer (NSCLC) being the major type, is the second most common malignancy and the leading cause of cancer-related death globally. Immunotherapy, represented by immune checkpoint inhibitors (ICIs), has been one of the greatest advances in recent years for the tre...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8982543/ https://www.ncbi.nlm.nih.gov/pubmed/35692863 http://dx.doi.org/10.1093/pcmedi/pbab027 |